Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Neutralizing antibodies for the prevention and treatment of COVID-19
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …
Epitope classification and RBD binding properties of neutralizing antibodies against SARS-CoV-2 variants of concern
A Deshpande, BD Harris, L Martinez-Sobrido… - Frontiers in …, 2021 - frontiersin.org
Severe acute respiratory syndrome coronavirus-2 (SAR-CoV-2) causes coronavirus disease
2019 (COVID19) that is responsible for short and long-term disease, as well as death, in …
2019 (COVID19) that is responsible for short and long-term disease, as well as death, in …
An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models
The Omicron variant continuously evolves under the humoral immune pressure exerted by
vaccination and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
vaccination and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2
Humoral immunity to SARS-CoV-2 can be supplemented with polyclonal sera from
convalescent donors or an engineered monoclonal antibody (mAb) product. While …
convalescent donors or an engineered monoclonal antibody (mAb) product. While …
Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections
HA Parray, S Shukla, R Perween, R Khatri… - Applied Microbiology …, 2021 - Springer
The route of administration of a therapeutic agent has a substantial impact on its success.
Therapeutic antibodies are usually administered systemically, either directly by intravenous …
Therapeutic antibodies are usually administered systemically, either directly by intravenous …
An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants
J Liu, F Mao, J Chen, S Lu, Y Qi, Y Sun, L Fang… - Nature …, 2023 - nature.com
Many of the currently available COVID-19 vaccines and therapeutics are not effective
against newly emerged SARS-CoV-2 variants. Here, we developed the metallo-enzyme …
against newly emerged SARS-CoV-2 variants. Here, we developed the metallo-enzyme …
Engineering ACE2 decoy receptors to combat viral escapability
T Arimori, N Ikemura, T Okamoto, J Takagi… - Trends in …, 2022 - cell.com
Decoy receptor proteins that trick viruses to bind to them should be resistant to viral escape
because viruses that require entry receptors cannot help but bind decoy receptors …
because viruses that require entry receptors cannot help but bind decoy receptors …
Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal …
H Ma, X Zhang, W Zeng, J Zhou, X Chi, S Chen… - Cell Discovery, 2022 - nature.com
Abstract Current SARS-CoV-2 Omicron subvariants impose a heavy burden on global health
systems by evading immunity from most developed neutralizing antibodies and vaccines …
systems by evading immunity from most developed neutralizing antibodies and vaccines …